US 11,851,467 B2
T-cell modulatory multimeric polypeptides and methods of use thereof
Ronald D. Seidel, III, Boston, MA (US); and Rodolfo J. Chaparro, Cambridge, MA (US)
Assigned to Cue Biopharma, Inc., Boston, MA (US)
Filed by Cue Biopharma, Inc., Boston, MA (US)
Filed on Dec. 13, 2022, as Appl. No. 18/080,275.
Application 17/131,104 is a division of application No. 16/812,926, filed on Mar. 9, 2020, granted, now 10,927,158, issued on Feb. 23, 2021.
Application 18/080,275 is a continuation of application No. 17/831,024, filed on Jun. 2, 2022, granted, now 11,530,248.
Application 17/831,024 is a continuation of application No. 17/131,104, filed on Dec. 22, 2020, granted, now 11,401,314, issued on Aug. 2, 2022.
Application 16/812,926 is a continuation of application No. 16/741,202, filed on Jan. 13, 2020, abandoned.
Application 16/741,202 is a continuation of application No. 16/462,443, abandoned, previously published as PCT/US2017/067663, filed on Dec. 20, 2017.
Claims priority of provisional application 62/582,132, filed on Nov. 6, 2017.
Claims priority of provisional application 62/555,435, filed on Sep. 7, 2017.
Claims priority of provisional application 62/470,774, filed on Mar. 13, 2017.
Claims priority of provisional application 62/438,272, filed on Dec. 22, 2016.
Prior Publication US 2023/0257439 A1, Aug. 17, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61P 21/00 (2006.01); C07K 14/005 (2006.01); C07K 14/55 (2006.01); A61K 35/17 (2015.01); C07K 14/47 (2006.01); C07K 14/74 (2006.01); G01N 33/50 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 14/55 (2013.01) [A61K 9/0019 (2013.01); A61K 35/17 (2013.01); C07K 14/005 (2013.01); C07K 14/4748 (2013.01); C07K 14/70539 (2013.01); G01N 33/5008 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/34 (2013.01); C07K 2319/30 (2013.01)] 20 Claims
 
1. A nucleic acid comprising:
a) a first nucleotide sequence encoding a first polypeptide comprising:
i) a human papillomavirus epitope; and
ii) first class I major histocompatibility complex (MHC) polypeptide, wherein the first MHC polypeptide is a β2-microglobulin (β2M) polypeptide;
b) a second nucleotide sequence encoding a second polypeptide comprising:
i) a second class I MHC polypeptide, wherein the second MHC polypeptide is an MHC Class I HLA-A heavy chain polypeptide;
ii) at least one immunomodulatory polypeptide, wherein the at least one immunomodulatory polypeptide is an IL-2 variant polypeptide that comprises an amino acid sequence having at least 98% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:44, wherein amino acid 16 is other than histidine and amino acid 42 is other than phenylalanine, wherein the percent sequence identity is determinable by a sequence alignment performed using BLAST; and
iii) an immunoglobulin (Ig) Fc polypeptide.